News und Analysen
Waters Establishes Flagship Innovation and Research Laboratory in Cambridge, MA
Waters Corporation (NYSE:WAT) announced this week at Biotech Week Boston the establishment of Immerse™ Cambridge, a new Waters' research laboratory in the heart of Cambridge’s Kendall Square
Illumina und die heilige GRAIL: Darum ist die Aktie abgestürzt!
Der US-amerikanische Biotechdienstleister Illumina (WKN: 927079) hat kürzlich die vollständige Übernahme der seinerzeit selbst gegründeten Tochtergesellschaft GRAIL für 7,1 Milliarden US-Dollar
Illumina und die heilige GRAIL: Darum ist die Aktie abgestürzt!
Der US-amerikanische Biotechdienstleister Illumina (WKN: 927079) hat kürzlich die vollständige Übernahme der seinerzeit selbst gegründeten Tochtergesellschaft GRAIL für 7,1 Milliarden US-Dollar
Illumina und die heilige GRAIL: Darum ist die Aktie abgestürzt!
Der US-amerikanische Biotechdienstleister Illumina (WKN: 927079) hat kürzlich die vollständige Übernahme der seinerzeit selbst gegründeten Tochtergesellschaft GRAIL für 7,1 Milliarden US-Dollar
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in
Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and
Humana and AtlantiCare Sign Medicare Network Agreement in Southeastern New Jersey
Leading health and well-being company Humana Inc. (NYSE: HUM) has signed an agreement with integrated healthcare system AtlantiCare that offers in-network access for Humana Medicare Advantage
Agilent Expands Line of Innovative Flow Cytometers with the NovoCyte Penteon
Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent NovoCyte Penteon, a sensitive flow cytometer with five lasers and up to 30 fluorescence channels. The NovoCyte Penteon
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. These include initial data from
Agilent Announces Cash Dividend of 18 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 18 cents per share of common stock will be paid on Oct. 28, 2020, to all shareholders of record as of the close of
Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial
Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic
DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today the first ever registry dedicated to tracking the outcomes of
Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic
DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today the first ever registry dedicated to tracking the outcomes of
Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune
Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas
As part of a two-day virtual Investor Day, Pfizer Inc. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on
Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas
As part of a two-day virtual Investor Day, Pfizer Inc. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on
Simulations Plus Releases ADMET Predictor® Version 10.0 (APX)
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic Neuropathy (LHON)
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System
Illumina (NASDAQ: ILMN) announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using
Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System
Illumina (NASDAQ: ILMN) announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using
Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System
Illumina (NASDAQ: ILMN) announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (“Anelixis”), a privately held clinical stage biotechnology company